Case Reports
A case of T-cell prolymphocytic leukaemia (T-PLL) effectively treated with Alemtuzumab, which is a new therapeutic agent for refractory CLL
2017 Volume 66 Issue 2 Pages 163-167
Details
2017 Volume 66 Issue 2 Pages 163-167
An 80-year-old woman presented with leukocytosis. Laboratory blood data showed a WBC count of 11,100/μL (LY 71.5%), a Hb level of 12.6 g/dL, and a PLT count of 29.1 × 104 /μL. Flow cytometric analysis results showed CD2+, CD3+, CD4+, CD5+, CD7+, and CD8+ cells. She was diagnosed as having T-PLL. Shortly thereafter, her condition worsened and treatment was started. Fludarabine as the first treatment or THP-COP as the second treatment was not effective. Then, Alemtuzumab (ALZ) treatment was started, which is a new drug against refractory CLL. Three days after starting the treatment, her WBC count became normal and her condition was improved. The duration of administration was 12 weeks, which was within the guidelines. Two months after the final dose, her condition became stable and she is now under treatment. This time, we obtained a result that makes us expect a recovery from T-PLL, which is considered a refractory disease. Now, it is very important in terms of quality assurance that we understand the causes of changes in laboratory data and correct information about new treatments and drugs.
